These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17161812)

  • 1. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine.
    Hirano T
    Int Immunopharmacol; 2007 Jan; 7(1):3-22. PubMed ID: 17161812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of cyclosporine cellular pharmacodynamics in minimal change nephrotic syndrome.
    Hirano T; Akashi T; Keira T; Oka K; Ihoya N; Yoshida M
    Clin Pharmacol Ther; 2000 Nov; 68(5):532-40. PubMed ID: 11103756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of immune monitoring in solid organ transplantation.
    Daniel V; Opelz G
    Int Rev Immunol; 2009; 28(3-4):155-84. PubMed ID: 19811320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics in solid organ transplantation: current status and future directions.
    de Jonge H; Kuypers DR
    Transplant Rev (Orlando); 2008 Jan; 22(1):6-20. PubMed ID: 18631854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immunobiogram, a Novel
    Portoles JM; Jimenez C; Janeiro D; Lopez-Oliva MO; Ortega-Carrion A; Blanquez D; Arribas L; Gomez C; Diez T; Pascual J; Portero I
    Front Immunol; 2020; 11():618202. PubMed ID: 33569062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.
    Herrlinger KR; Jewell DP
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1403-12. PubMed ID: 17081161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies.
    Creed TJ; Probert CS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):111-22. PubMed ID: 17229236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics: the key to improved drug therapy in transplant patients.
    Burckart GJ
    Clin Lab Med; 2008 Sep; 28(3):411-22, vi. PubMed ID: 19028260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive efficacy of roxithromycin against human peripheral-blood mononuclear cells stimulated with hemolytic streptococci superantigen.
    Kamogawa S; Kagami K; Maeda M; Arai K; Okubo Y; Tsuboi R; Hirano T
    Eur J Pharmacol; 2009 Jan; 602(2-3):439-47. PubMed ID: 19068210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients.
    Millán O; Urtasun N; Brunet M
    Transplant Rev (Orlando); 2009 Apr; 23(2):120-8. PubMed ID: 19298943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
    Atreya I; Neurath MF
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):23-34. PubMed ID: 19072367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
    Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
    Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological risk factors for infection after immunosuppressive and biologic therapies.
    Carbone J; del Pozo N; Gallego A; Sarmiento E
    Expert Rev Anti Infect Ther; 2011 Apr; 9(4):405-13. PubMed ID: 21504398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can immune monitoring help to minimize immunosuppression in kidney transplantation?
    Ashton-Chess J; Giral M; Soulillou JP; Brouard S
    Transpl Int; 2009 Jan; 22(1):110-9. PubMed ID: 18764832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized immunosuppression: new strategies from pharmacokinetics, pharmacodynamics and pharmacogenomics.
    Chen G; Dong JH
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):332-8. PubMed ID: 16109511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we ready for top-down therapy for inflammatory bowel diseases: pro.
    van der Woude CJ; Hommes DW
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):243-8. PubMed ID: 19072416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms of action of some immunosuppressive drugs].
    Liberman AC; Druker J; Refojo D; Arzt E
    Medicina (B Aires); 2008; 68(6):455-64. PubMed ID: 19147430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.